Home/Filings/4/0000950170-22-025513
4//SEC Filing

Wellington Biomedical Innovation Master Investors (Cayman) I L.P. 4

Accession 0000950170-22-025513

CIK 0001781174other

Filed

Nov 20, 7:00 PM ET

Accepted

Nov 21, 1:22 PM ET

Size

7.1 KB

Accession

0000950170-22-025513

Insider Transaction Report

Form 4
Period: 2022-11-17
Transactions
  • Conversion

    Common Stock

    2022-11-17+888,130888,130 total
  • Conversion

    Series B Preferred Stock

    2022-11-172,190,1310 total
    Common Stock (888,130 underlying)
Footnotes (1)
  • [F1]On November 17, 2022, the Series B Preferred Stock automatically converted into Common Stock on a 1-to-2.466 basis without payment of further consideration upon the closing of the initial public offering of the Issuer's common stock. The Series B Preferred Stock had no expiration date.

Documents

1 file

Issuer

Acrivon Therapeutics, Inc.

CIK 0001781174

Entity typeother
IncorporatedCayman Islands

Related Parties

1
  • filerCIK 0001787092

Filing Metadata

Form type
4
Filed
Nov 20, 7:00 PM ET
Accepted
Nov 21, 1:22 PM ET
Size
7.1 KB